Compositions and methods for modulating apolipoprotein (a) expression
AssigneeIonis Pharmaceuticals, Inc.
InventorsThazha P. Prakash, Punit P. Seth, Eric E. Swayze, Mark J. Graham
Life of this patent
Estimating the term…
Loading patent…
AssigneeIonis Pharmaceuticals, Inc.
InventorsThazha P. Prakash, Punit P. Seth, Eric E. Swayze, Mark J. Graham
Estimating the term…
Provided herein are oligomeric compounds with conjugate groups targeting apoplipoprotein (a) [apo(a)]. In certain embodiments, the apo(a) targeting oligomeric compounds are conjugated to N-Acetylgalactosamine. Also disclosed herein are conjugated oligomeric compounds targeting apo(a) for use in decreasing apo(a) to treat, prevent, or ameliorate diseases, disorders or conditions related to apo(a) and/or Lp(a). Certain diseases, disorders or conditions related to apo(a) and/or Lp(a) include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The conjugated oligomeric compounds disclosed herein can be used to treat such diseases, disorders or conditions in an individual in need thereof.
A method for treating a disease related to elevated Lp (a) comprising administering to a human in need a compound, wherein the compound has the formula:
A method for preventing a disease related to elevated Lp (a) comprising administering to a human in need a compound or pharmaceutically acceptable salt thereof, wherein the compound has the formula:
A pharmaceutically acceptable salt of a compound having the formula:
Dependencies are inferred from the claim text.